CN1524581A - Polymer micelle medicine-carrying system - Google Patents
Polymer micelle medicine-carrying system Download PDFInfo
- Publication number
- CN1524581A CN1524581A CNA031053483A CN03105348A CN1524581A CN 1524581 A CN1524581 A CN 1524581A CN A031053483 A CNA031053483 A CN A031053483A CN 03105348 A CN03105348 A CN 03105348A CN 1524581 A CN1524581 A CN 1524581A
- Authority
- CN
- China
- Prior art keywords
- protein
- micelle
- polypeptide
- molecule
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000693 micelle Substances 0.000 title claims abstract description 70
- 229920000642 polymer Polymers 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 54
- 238000002360 preparation method Methods 0.000 claims abstract description 41
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 22
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 20
- 229920000728 polyester Polymers 0.000 claims abstract description 13
- 229920001577 copolymer Polymers 0.000 claims abstract description 9
- 238000011068 loading method Methods 0.000 claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- -1 dimethyl sulfoxine Chemical compound 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 13
- 229960005420 etoposide Drugs 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 229930012538 Paclitaxel Natural products 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 229940041181 antineoplastic drug Drugs 0.000 claims description 11
- 229960001592 paclitaxel Drugs 0.000 claims description 11
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 7
- 239000004626 polylactic acid Substances 0.000 claims description 7
- 150000005846 sugar alcohols Polymers 0.000 claims description 7
- 239000004530 micro-emulsion Substances 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 239000003495 polar organic solvent Substances 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 238000012377 drug delivery Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 4
- 108010033708 GFE-1 peptide Proteins 0.000 claims description 4
- 102000002068 Glycopeptides Human genes 0.000 claims description 4
- 108010015899 Glycopeptides Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 102000013275 Somatomedins Human genes 0.000 claims description 4
- 210000004100 adrenal gland Anatomy 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- 210000000952 spleen Anatomy 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- 210000004026 tunica intima Anatomy 0.000 claims description 4
- 210000004291 uterus Anatomy 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000003178 anti-diabetic effect Effects 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 239000002327 cardiovascular agent Substances 0.000 claims description 3
- 229940125692 cardiovascular agent Drugs 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 150000002433 hydrophilic molecules Chemical class 0.000 claims description 2
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 229940084106 spermaceti Drugs 0.000 claims description 2
- 239000012177 spermaceti Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 17
- 230000008901 benefit Effects 0.000 abstract description 3
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 42
- 239000002904 solvent Substances 0.000 description 21
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 13
- 239000006185 dispersion Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 229920001400 block copolymer Polymers 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 238000005227 gel permeation chromatography Methods 0.000 description 7
- 229940090044 injection Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 238000000295 emission spectrum Methods 0.000 description 5
- 238000000695 excitation spectrum Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002798 polar solvent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010025 steaming Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229920001427 mPEG Polymers 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 229940108949 paclitaxel injection Drugs 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 2
- 229930195573 Amycin Natural products 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 229940124623 antihistamine drug Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000004017 vitrification Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- VYWWNRMSAPEJLS-MDWYKHENSA-N Rokitamycin Chemical compound C1[C@](OC(=O)CC)(C)[C@@H](OC(=O)CCC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C VYWWNRMSAPEJLS-MDWYKHENSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229950009438 acedapsone Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- CNWSQCLBDWYLAN-UHFFFAOYSA-N butylurea Chemical compound CCCCNC(N)=O CNWSQCLBDWYLAN-UHFFFAOYSA-N 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960000729 cyclandelate Drugs 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 229930189064 deacetyllanatoside Natural products 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960003203 erythromycin estolate Drugs 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 description 1
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
- 229940075383 etoposide injection Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 239000008384 inner phase Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960002614 lanatoside c Drugs 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 description 1
- 229960000989 perhexiline Drugs 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 229960004572 pizotifen Drugs 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- XUBKCCSAVNRWOX-BVHPQESASA-N rifandin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2N1CCN(CC(C)C)CC1 XUBKCCSAVNRWOX-BVHPQESASA-N 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- 229960001170 rokitamycin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a method for making medicinal preparation, in particular a polymer micelle drug loading system and preparation, wherein the micelle is methyl polyethylene glycol - polyester segmented copolymer micelle, characterized by that, the ratio of methyl polyethylene glycol and polyester is less than 50/50, and the advantages of the segmented copolymer micelle is low critical micelle concentration, high drug loading capacity and stabilized micelle.
Description
Technical field:
The present invention relates to a kind of drug preparation technique, particularly relate to medicine carrying system of polymer micelle and preparation thereof.
Background technology:
The biggest obstacle of the administration of insoluble drug (particularly drug administration by injection) is that dissolubility is low, is difficult to prepare suitable preparation.Often need to take the way of various increase dissolubility, as with the medication preparation salify, add the latent solvent matchmaker, add cosolvent and add surface active agent solubilization.Because salify often needs strong acid or highly basic condition, and is often inapplicable to many medicines; The latent solvent matchmaker of physiological safety seldom, and consumption is limited; By forming difficult assurance of safety that complex increases the cosolvent of drug solubility with medicine; Comparatively speaking, because comparatively safe surfactant can obtain, therefore, often become first-selection by the surfactant micella solubilising.Medicine for the water solublity extreme difference often needs to adopt simultaneously several measures, and this often causes many deficiencies, thereby influences the effect of medicine.For example paclitaxel is the very strong antitumor drug of a kind of effect, and in vitro tests shows that paclitaxel all has the obvious suppression effect to various tumors, is applicable to treatment breast carcinoma, ovarian cancer and carcinoma of prostate etc. clinically.Yet since its dissolubility low (being lower than 1 μ g/ml), its oral absorption hardly, and drug administration by injection needs special solvent system, a kind of mixed solvent of being made up of polyoxyethylene castor oil (Cremophor EL) and ethanol.This paclitaxel injection solvent by the mixed solvent preparation itself has bigger side effect, particularly polyoxyethylene castor oil can cause severe anaphylactic reaction, even threat to life, for preventing anaphylaxis, before using paclitaxel injection, need injection cortex steroid hormone and/or antihistamine drug clinically, yet, even if inject cortex steroid hormone and/or antihistamine drug in advance, a large amount of patients still exists slightly, the anaphylaxis of moderate and even severe; On the other hand, this injection with diluent (as normal saline) when mixing, because the micellar critical micelle concentration of polyoxyethylene castor oil (Critical micellar concentration, CMC) height, micelle dissociates easily, cause medicine to be separated out, therefore, many paclitaxels are preceding the filtration outside filter membrane in entering body, cause bioavailability not high, and the bioavailability of paclitaxel injection is all different with different pharmaceutical speed of separating out, the degree of mixed method, causes the individual variation of bioavailability big.For these reasons, clinical application of taxol is very limited.Same situation also appears in the injection of antitumor drug such as camptothecine, etoposide, and for example the etoposide injection is made up of ethanol, propylene glycol, polyoxyethylene sorbitan monoleate, uses preceding dilution, and this injection zest is bigger.
In view of micellar high CMC of conventional surfactants and possible toxic and side effects, in recent years, the someone has studied the micelle medicine carrying system of amphipathic nature block polymer.Document Torchilin sees reference, V.P., Structure and design ofpolymeric surfactant-based drug delivery systems.J Control Release, 2001.73 (2-3): p.137-72. wherein the mPEG-PDLLA micellar system has attracted extensive concern.Document Yamamoto sees reference, Y., et al., Long-circulatingpoly (ethylene glycol)-poly (D, L-lactide) block copolymermicelles with modulatedsurface charge.J Control Release, 2001.77 (1-2): p.27-38. mPEG-PDLLA adopts ring-opening polymerisation and gets, after soon lactide and methoxypolyethylene glycol Hybrid Heating (120-140 ℃) will make the lactide dissolving, add catalyst (as stannous octoate), get 150-180 ℃ of following polymerization.Resulting polymers contains hydrophilic segment (Polyethylene Glycol) and hydrophobic part (polylactic acid) simultaneously owing in the structure, thereby can form micelle in aqueous solution.The CMC of this polymer micelle is relatively low, and its solubilizing systems need not add the latent solvent matchmaker.For example, someone adopts mPEG: the PLA ratio is 50/50,60/40,70/30 mPEG-PDLLA has prepared the paclitaxel micelle medicine carrying system, the result shows, micellar CMC descends with the ratio reduction of mPEG, wherein 50/50 o'clock CMC is 0.16mg/ml, the micellar system of preparation is external and the intravital biocompatibility of animal is better, do not see overt toxicity, the experiment that distributes in the paclitaxel isotope body shows that micelle dissociates rapidly after entering in the body, discharge medicine, polymer can be degraded in 15 hours in vivo.Document Zhang sees reference, X., et al., Anti-tumor efficacy and biodistribution ofintravenous polymeric micellar paclitaxel.Anticancer Drugs, 1997.8 (7): p.696-701.Kim, S.C., et al., In vivo evaluation of polymeric micellar paclitaxelformulation:toxicity and efficacy.J Control Release, 2001.72 (1-3): p.191-202..
At present, the method for having delivered for preparing paclitaxel-mPEG-PDLLA micellar system is divided into three phases: at first medicine, block copolymer are dissolved in a kind of common solvent; Boil off solvent then and obtain medicine-block copolymer wax sample solid dispersion; At last, descend continuous vortex joltings to being uniformly dispersed at 60 ℃ wax sample solid.Because the micelle disperse system less stable that makes, having the people further will be scattered in micelle lyophilization in the water, to prepare lyophilized powder standby.Because this method needs continuous vortex jolting wax sample solid dispersion, complicated operation, even if it is the dispersion of lyophilized powder is also time-consuming bothersome, very inconvenient when clinical practice.Micelle is a kind of thermodynamic unstable system, adopt dispersion method to prepare the huge energy of micelle needs solid, and thisly prepare micellar method by the vortex jolting and often be difficult to be competent at for its energy of mPEG-PDLLA micelle of the low methyl Polyethylene Glycol ratio of preparation, therefore, so far the methyl polyethylene glycol-ester block copolymer that is used to prepare micellar system all be methyl Polyethylene Glycol and polyester ratio greater than 50/50, and ratio just is used to prepare microsphere or millimicro ball less than 50/50.
The targeted therapy of tumor starts from nineteen forties " magic bullet " imagination.Because the huge toxic and side effects of antitumor drug, the pharmaceuticals researcher wishes that medicine has targeting, promptly only to tumor cell generation toxic action.Nanoparticle drug-loading system (as liposome, millimicro ball, micelle) is because drug loading is big, be considered to can prolong drug body in average residence time, improve the targeting of treatment.Yet, for Liposomal formulation, because gulping down of reticuloendothelial system (RES) sneered, from systemic circulation, be eliminated rapidly after in they enter body, therefore, Liposomal formulation can solve the solubility problem of insoluble drug, still, can not reduce toxic and side effects, improve the therapeutic index and the targeting of medicine.In recent years, the recessive liposome of amycin (Stealthy liposome) that contains the methyl phosphatidylcholine is proved to be the biological half-life that can improve medicine, can reduce the cardiac toxicity of amycin.The research of recessive millimicro ball also has similar result.Recently, micelle is considered to have better targeting drug delivery system and obtains broad research, different with liposome, nanoparticle, the micelle particle diameter is littler, be easier to discharge medicine in vivo, especially polymer micelle is because PEG hydrated sheath that the surface exists and little particle diameter, is easier to avoid gulped down by the RES system sneer.Yet because the surface does not have the molecule that has with the special affinity of target site, initiatively targeting is still lower for it.
To studies show that of tomour specific affinity molecule: many materials have special affinity to various tissues, can be used to organize or the cancer target of cell or molecular level.This quasi-molecule comprises protein with tissue or cell-specific or polypeptide, somatomedin, vitamin and analog thereof (as folic acid), polysaccharide, glycopeptide or glycoprotein, steroidal and analog thereof, hormone, cofactor, genetic molecule, some drugs molecule.As to brain special contain CNSRLHLRC, CENWWGDVC, the segmental polypeptide of WRCVLREGPAGGCAWFNRHRL and CLSSRLDAC, protein; Kidney-specific contained CLPVASC and the segmental polypeptide of CGAREMC, protein; To lung special contain CGFECVRQCPERC, CGFELETC, the segmental polypeptide of CTLRDRNC and CIGEVEVC, protein; To skin special contain the segmental polypeptide of CVALCREACGEGC, protein; To spleen special contain the segmental polypeptide of SWCEPGWCR, protein; To small intestinal special contain the segmental polypeptide of YSGKWGW, protein, to the uterus special contain the segmental polypeptide of GLSGGRS, protein; To the adrenal gland special contain the segmental polypeptide of LMLPRAD, protein; To retinal tissue special contain CRDVVSVIC and the segmental polypeptide of CSCFRDVCC, protein; Have the polypeptide, the protein that suppress integral protein express cell and extracellular matrix protein combination, this proteinoid or polypeptide contain CRGDC, CRGDCL, NGR (AHA), DGR (AHA), CRGDCA, RCDVVV, SLIDIP, TIRSVD, KRGD, RRGP and RGDL fragment; Antibody with tumour-specific; To the solid tumor tunica intima special contain CDCRGDCFC and the segmental polypeptide of CNGRCVSGCAGRC, protein; And other have the molecule of special affinity to tumor cell.
Summary of the invention:
The invention provides a kind of amphipathic nature polyalcohol, by the methyl Polyethylene Glycol, polyester is made, and it is characterized in that, in the proportioning that copolymer is formed, the mass ratio of methyl Polyethylene Glycol and polyester is lower than 50/50.Polyester wherein is selected from, polylactic acid, polyglycolic acid (polyglycolide)), glycolide-lactide copolymer (poly (lactide-co-glycolide), PLGA).
The invention provides the micellar preparation method of a kind of amphipathic nature polyalcohol, it is characterized in that, by the following steps preparation,
A. medicine and Amphipathilic block polymer are dissolved in the polar organic solvent,
B. drip and add water in the solution, or will make into microemulsion in the drips of solution entry,
C. boil off polar organic solvent.Wherein said polar organic solvent is selected from, acetonitrile, ethanol, dimethyl sulfoxine (DMSO), dimethyl formamide, methanol, dichloromethane, chloroform.
The invention provides a kind of amphipathic nature polyalcohol micelle medicine carrying system, is the drug delivery system composition that is aligned (hydrophilic group is outside, and lipophilic group is inside) by the micelle of above preparation method preparation, and the medicine carrying is in micelle.Drug-loading system of the present invention, its contained medicine is selected from, antitumor drug, antibiotic, cardiovascular drugs, antidiabetic medicine, NSAID (non-steroidal anti-inflammatory drug).
The present invention also provides a kind of tumour target polymer micelle administration system, it is characterized in that, this system is by antitumor drug, and amphipathic nature polyalcohol of the present invention is formed with the surfactant with cancer target characteristic.Wherein said surfactant with cancer target effect has the molecule of tumor affinity and the amphiphile, amphiphilic molecule that hydrophobic molecule is formed by hydrophilic.The hydrophilic molecule that wherein has tumor affinity comprises following material, have the protein of tissue or cell-specific or polypeptide, somatomedin, vitamin and analog thereof, polysaccharide, glycopeptide or glycoprotein, steroidal and analog thereof, hormone, cofactor, genetic molecule, to brain special contain CNSRLHLRC, CENWWGDVC, the segmental polypeptide of WRCVLREGPAGGCAWFNRHRL and CLSSRLDAC, protein; Kidney-specific contained CLPVASC and the segmental polypeptide of CGAREMC, protein; To lung special contain CGFECVRQCPERC, CGFELETC, the segmental polypeptide of CTLRDRNC and CIGEVEVC, protein; To skin special contain the segmental polypeptide of CVALCREACGEGC, protein; To spleen special contain the segmental polypeptide of SWCEPGWCR, protein; To small intestinal special contain the segmental polypeptide of YSGKWGW, protein, to the uterus special contain the segmental polypeptide of GLSGGRS, protein; To the adrenal gland special contain the segmental polypeptide of LMLPRAD, protein; To retinal tissue special contain CRDVVSVIC and the segmental polypeptide of CSCFRDVCC, protein; Have the polypeptide, the protein that suppress integral protein express cell and extracellular matrix protein combination, this proteinoid or polypeptide contain CRGDC, CRGDCL, NGR (AHA), DGR (AHA), CRGDCA, RCDVVV, SLIDIP, TIRSVD, KRGD, RRGP and RGDL fragment; Antibody with tumour-specific; To the solid tumor tunica intima special contain CDCRGDCFC and the segmental polypeptide of CNGRCVSGCAGRC, protein; And other have the molecule of special affinity to tumor cell, during hydrophobic molecule is selected from, long-chain fatty acid, in, long-chain fatty alcohol, stearic acid, stearyl alcohol, spermaceti acid, spermol, lauric acid, lauryl alcohol.Wherein said antitumor drug is selected from paclitaxel, Docetaxel, camptothecine, etoposide.
The objective of the invention is to, a kind of new method for preparing medicine carrying system of polymer micelle is provided, and this method adopts microemulsified-solvent evaporated method, and promptly polymer and medicine are dissolved in a kind of polar solvent, drip water and make into microemulsion, boil off polar solvent and promptly get micelle medicine carrying system.The advantage of this method is can be simple to operate, favorable reproducibility, and yield is higher, is applicable to the preparation of the medicine carrying system of polymer micelle of various scales simultaneously, comprises laboratory scale and big production.
The ratio that the present invention also provides methyl Polyethylene Glycol and polyester is less than 50/50 methyl polyethylene glycol-ester block copolymer (methoxypolyethylene glycol-block-polyester) micelle, this block copolymer micelle has critical micelle concentration (critical micellar concentration, CMC) low, micelle medicine carrying amount height, the advantage that micelle is stable.
The micelle that the present invention also provides amphipathic nature block polymer and various surfactant with cancer target to form.This system has the higher characteristics of targeting.
(1) polymer drug-carried micelle of the present invention adopts microemulsified-solvent evaporated method preparation, can pass through following steps: 1, block polymer, medicine are dissolved in the polar solvent, polar solvent comprises acetonitrile, ethanol, dimethyl sulfoxine (DMSO), dimethyl formamide, methanol etc.2, under agitation slowly drip water and make into the W/O microemulsion, the phase volume ratio of oil phase and water is usually greater than 50/50 at this moment.3, under agitation further splash into the water of capacity, make the variation generation inversion of phases of microemulsion, generate the O/W microemulsion because of phase volume ratio, the time oil phase and water phase volume ratio usually less than 50/50.4, about 60 ℃, boil off organic solvent under the vacuum condition and get the carrier micelle system.Look stability of drug further filtration sterilization or pressure sterilizing for injection.
Distillation is crucial in the above-mentioned preparation method, should guarantee to remove polar solvent, guarantees envelop rate again.Vapo(u)rizing temperature should be about the vitrification point of block polymer, and temperature is crossed low solvent and is difficult for leaving micelle, and the too high inner phase viscosity that will cause of temperature reduces, and medicine may dissociate and separate out, and envelop rate is descended; Vacuum is unsuitable too high, should be controlled in the bubble-tight scope usually, treat that most of solvent has steamed after, gas clean-up and temperature eliminate solvent.
The size of the micelle medicine carrying system that the employing said method makes is in the 10-100nm scope, such particle size range can guarantee that the micelle intravasation organizes (this is that the following targeting drug delivery system that will mention is necessary) outward, does not have the danger that causes capillary embolism simultaneously.Particularly the disperse system of this particle diameter can be easily by the sterilization of filtration method (be the filter membrane filtration sterilization of 0.22 μ m as adopting the aperture).
(2) at present the methyl polyethylene glycol-ester block copolymer micelle medicine carrying system of report all is to select methyl Polyethylene Glycol and polyester ratio greater than 50/50 mPEG-PDLLA (being meant the amount of the amount of methyl Polyethylene Glycol greater than polyester greater than 50/50), yet because CMC height, the concentration of copolymer must be greater than CMC in the preparation, nonetheless, its physical stability is still undesirable.The present invention has improved this situation, the Polyethylene Glycol ratio is reduced to less than 50/50, the CMC of block polymer also decreases, while is for the methyl Polyethylene Glycol of same molecular weight, its ratio in copolymer is low more, the molecular weight of copolymer that makes is big more, and hydrophobic part is big more, thereby can improve drug loading and physical stability.
(3) studies show that the tomour specific affinity molecule: many hydroaropic substances have special affinity to various tissues, can be used to organize or the cancer target of cell or molecular level.This quasi-molecule comprises protein with tissue or cell-specific or polypeptide, somatomedin, vitamin and analog thereof (as folic acid), polysaccharide, glycopeptide or glycoprotein, steroidal and analog thereof, hormone, cofactor, genetic molecule, some drugs molecule.As to brain special contain CNSRLHLRC, CENWWGDVC, the segmental polypeptide of WRCVLREGPAGGCAWFNRHRL and CLSSRLDAC, protein; Kidney-specific contained CLPVASC and the segmental polypeptide of CGAREMC, protein; To lung special contain CGFECVRQCPERC, CGFELETC, the segmental polypeptide of CTLRDRNC and CIGEVEVC, protein; To skin special contain the segmental polypeptide of CVALCREACGEGC, protein; To spleen special contain the segmental polypeptide of SWCEPGWCR, protein; To small intestinal special contain the segmental polypeptide of YSGKWGW, protein, to the uterus special contain the segmental polypeptide of GLSGGRS, protein; To the adrenal gland special contain the segmental polypeptide of LMLPRAD, protein; To retinal tissue special contain CRDVVSVIC and the segmental polypeptide of CSCFRDVCC, protein; Have the polypeptide, the protein that suppress integral protein express cell and extracellular matrix protein combination, this proteinoid or polypeptide contain CRGDC, CRGDCL, NGR (AHA), DGR (AHA), CRGDCA, RCDVVV, SLIDIP, TIRSVD, KRGD, RRGP and RGDL fragment; Antibody with tumour-specific; To the solid tumor tunica intima special contain CDCRGDCFC and the segmental polypeptide of CNGRCVSGCAGRC, protein; And other have the molecule of special affinity to tumor cell.The present invention is with this quasi-molecule and lipophilic molecules (as stearic acid) covalent bond, obtain a kind of new surfactant, when the preparation polymer micelle, add this surfactant, it is aligned in micellar surface, targeted molecular can reach the purpose of cancer target outwardly afterwards.
(4) block polymer micelle that relates in this patent can be used for the various hydrophobic drugs of carrying, comprises that antitumor drug is (as paclitaxel, 5-fluorouracil, etoposide, melphalan, chlorambucil, hexamethylmelamine, methotrexate, CH3-CCNU, NVB, teniposide, homoharringtonine, hydroxycamptothecin etc.), antibiotic is (as chloromycetin, erythromycin, erythromycin estolate, erythromycin ethylsuccinate, midecamycin, josamycin, clarithromycin, rokitamycin, sulfadiazine, trimethoprim, nitrofurantoin, sharp secondary flat, rifaximin, Rifandin, dapsone, acedapsone, narrow health azoles etc.), cardiovascular drugs is (as nifedipine, nicardipine, nitrendipine, nilvadipine, cinnarizine, perhexiline, molsidomine, digitophyllin, digoxin, cedilanid, deacetyllanatoside, Propafenone, amiodarone, nitroglycerin, pentaerithrityl tetranitrate, cyclandelate, tocopheryl nicotinate etc.), antidiabetic medicine is (as the yellow butyl urea of toluene, glibenclamide, glipizide etc.), NSAID (non-steroidal anti-inflammatory drug) (is drained dry the spit of fland as the chlorine horse, Cyproheptadine, pizotifen, ketotifen, Qu Nisi etc.).
The mensuration of block polymer CMC: though light scattering technique and gel chromatography can be used to measure CMC, the CMC assay method is generally acknowledged accurately, reliably is fluorescent spectrometry, and this method is promptly adopted in the acquisition of the CMC value in this patent.Fluorescent spectrometry need be suitable for a kind of fluorescent probe material (fluorescence probe), and commonly used is pyrene.Pyrene is a kind of hydrophobicity aromatic, to the environment polar sensitive.When the concentration of amphiphile, amphiphilic molecule is lower than CMC, can not form micelle in the solution, pyrene is dissolved in the polar water; Along with the concentration of amphiphile, amphiphilic molecule is higher than CMC, micelle formation, pyrene distributes to the hydrophobic part of micelle kernel, thereby enter nonpolar environment, then in its fluorescence spectrum, can observe a series of variations, will increase, vibrate fine structure (the vibrational fine structure of the emission spectra) in the emission spectra and change as fluorescence intensity, (0,0) wave band red shift in the excitation spectrum.Therefore, by with I in the emission spectra of pyrene
1/ I
3Than (under fixed excitation wavelength, scanning I
1, I
3Represent respectively in the emission spectra first and the fluorescence intensity ratio at three strongest ones peak) or excitation spectrum in I
338/ I
333Can obtain the apparent CMC of amphiphile, amphiphilic molecule to the concentration mapping of amphiphile, amphiphilic molecule than (the excitation spectrum medium wavelength is respectively the fluorescence intensity ratio of 338nm and 333nm).The point that slope changes among the figure promptly is to form micellar critical point, and the concentration of corresponding amphiphile, amphiphilic molecule promptly is CMC.During the CMC of fluorescence spectrum method for measuring amphiphile, amphiphilic molecule, the concentration of pyrene should very lowly (be generally 10
-7M), only in this way could detect the variation of slope, in addition, should get rid of of the effect of other lyophobic dusts during mensuration fluorescence spectrum at the critical micelle concentration point.Sometimes can adopt anisotropy (anisotropy) fluorescent spectrometry.
The assay method of the micelle particle diameter that relates in this patent be dynamic light scattering method (dynamic lightscattering, DLS).
The envelop rate of medicine is meant that the medicine that is encapsulated in the micelle accounts for the ratio of the medicine of adding, and it plays the certainly dose of adding and the oleophylic/hydrophilic ratio of amphiphile, amphiphilic molecule when preparation.
The specific embodiment:
Be the embodiment of this patent below, but following embodiment does not limit the interest field of putting this patent.
Present embodiment is the mensuration of the preparation of mPEG-PDLLA of preparation etoposide and molecular weight, CMC
Materials and methods
D, the L-lactide: available from Sigma company, with preceding employing anhydrous ethyl acetate in 60 ℃ of recrystallization three times, under the room temperature at P
2O
5Middle vacuum drying 24 hours.Etoposide, stannous octoate and methyl Polyethylene Glycol (molecular weight 2000) are all available from Sigma company.
1. mPEG-PDLLA is synthetic:
Adopt ring-opening polymerization method, the preparation quality ratio is 5/95 respectively, or 20/80, or 50/50 mPEG-PDLLA.A) take by weighing methyl Polyethylene Glycol 0.5g and lactide 9.5g prepares 5/95 mPEG-PDLLA; B) take by weighing methyl Polyethylene Glycol 2g and lactide 8g and prepare 20/80 mPEG-PDLLA; C) take by weighing methyl Polyethylene Glycol 5g and lactide 5g and prepare 50/50 mPEG-PDLLA.Methyl Polyethylene Glycol and lactide are placed airtight reactor, be warming up to 120-140 ℃ and make the solid fusing under stream of nitrogen gas, add stannous octoate 50mg, elevated temperature was to 150-180 ℃ of reaction 3-6 hour.Cooling gets the white solid crude product.Crude product under agitation adds in the 100ml ether after dissolving with dichloromethane 5ml, filters, and three times repeatedly, product vacuum drying 24 hours gets final product.
2. the mensuration of mPEG-PDLLA molecular weight:
The mensuration of mPEG-PDLLA molecular weight adopts gel chromatography.The GPC chromatographic column is Styragel (HR 5E, 4.6 * 300mm, Waters), detector is differential refractometer detector (Differential Refractometer Detector, JASCO, RI-930), mobile phase is dimethyl formamide (DMF), and flow velocity 1.5ml/min, column temperature are 60 ℃, sample is dimethyl formamide (DMF) solution of the block copolymer of above-mentioned three kinds of different proportions of 0.1%, sample size 100 μ l.(Wis.) calibrate for Aldrich, Milwaukee by standard curve with polystyrene standards for chromatographic column.
Fig. 1,2,3 is respectively the GPC chromatogram of mPEG-PDLLA, can see two chromatographic peaks are all arranged in chromatogram, wherein the short peak of retention time is micellar peak (this peak diminishes with the dilution of sample appropriateness even disappears), and monomeric retention time is positioned at back (this peak does not have significant change when appropriateness is diluted).Table 1 is the molecular weight that calculates according to standard curve.
Three kinds of mPEG-PDLLAs of table 1 and micellar weight thereof, CMC measurement result
Molecular number CMC (μ g/ml) in the mPEG/PLA monomer molecule amount micellar weight micelle
The theoretical value measured value
50/50?????4000????????17762????1566610????????88???????????45.61
20/80?????12000???????58761????1478920????????25???????????1.92
5/95??????40000???????89869????1429005????????16???????????0.35
3. the mensuration of mPEG-PDLLA NMR, DSC:
The NMR of above-mentioned three kinds of mPEG-PDLLAs (the D-chloroform is a solvent) collection of illustrative plates is respectively 5/95 (Fig. 4) with the methyl Polyethylene Glycol in 5.2ppm (PLA) and 3.6ppm (PEG) the peak area ratio affirmation polymer and the mass ratio of polylactic acid, 20/80 (Fig. 5) and 50/50 (Fig. 6).The vitrification point that DSC records three kinds of polymer is respectively 36.7 (Fig. 7), 46.3 (Fig. 8), 50.2 ℃ (Fig. 9).
4. the mensuration of mPEG-PDLLA CMC:
MPEG-PDLLA CMC adopts pyrene steady-state fluorescence spectrographic determination (steady-state pyrene fluorescence method).The concentration that with acetone is solvent preparation pyrene is 6 * 10
-6The solution of M is got 1ml respectively and is placed 10 10ml measuring bottles for each 10 parts, flings to acetone with nitrogen current, it is an amount of and be diluted to scale and make polymer concentration become 0.1,0.2,0.5 to add the aqueous solution of polymer respectively, 1.0,5.0,10.0,50.0,100.0,500.0, the solution of 1000.0,2000.0 μ g/ml.Above-mentioned solution places 65-70 ℃ of water-bath insulation 1 hour, takes out, and room temperature underlying dark place is placed and spent the night.(Photon Technology International USA) goes up emission spectra (360-460nm, excitation wavelength 390nm) and the excitation spectrum (300-360nm, emission wavelength 390nm) of drawing pyrene for LPS-220 (B), MD-5020 at fluorophotometer.Write down the I of each solution excitation spectrum
338/ I
333With I
338/ I
333To the mapping of polymer logarithm concentration, calculate CMC (table 1).
Micellar preparation of etoposide-mPEG-PDLLA and particle size determination
1. the micellar preparation of etoposide-mPEG-PDLLA
Take by weighing the 50mg etoposide respectively and the 100mg mPEG-PDLLA places flask, add acetonitrile 50ml, be stirred to dissolving.Under constantly stirring, slowly drip 25ml water, continue to stir 15 minutes, further drip 75ml water.Slowly boil off acetonitrile (Rotary Evaporators) under 60 ℃, vacuum, after waiting not have obvious acetonitrile and steaming, elevated temperature and vacuum continue to steam to the about 80ml of sample volume, and samples with water is adjusted volume to 100ml.Product is with 0.22mm microporous filter membrane Entkeimung.
2. the micellar particle size determination of etoposide-mPEG-PDLLA
(DynaPro 99, and Proteinsolutions USA) measures the micelle particle diameter, and angle of scattering is 90 °, and data are with the spherical model collection, with DynaPro Version 5.1.25 computed in software to adopt dynamic light scattering method.It is that the micelle particle diameter of 50/50,20/80,5/95 block copolymer is respectively 65.63nm, 50.48nm, 50.02nm that the result records methyl polyethylene glycol-lactic acid ratio.
The preparation of the preparation stearic acid-N-butanimide of RGD-stearic amide: get 0.02 mole of stearic acid and 0.02 mole of N-hydroxy-succinamide, make in 0 ℃ of continuous stirring to be dissolved in the 20ml oxolane.Add 0.02 mole of dicyclohexylcarbodiimide, under room temperature, stir and spend the night.Remove by filter solvent, residue washs with sodium bicarbonate, and uses recrystallizing methanol.The preparation of dimethyl RGD: (Arg-Gly-Asp tripeptide Bachem) is dissolved in the 20ml methanol, is incubated in 0 ℃ to get 500mg RGD.Adding 2ml thionyl (two) chlorine at room temperature stirs and spends the night.The pressure reducing and steaming solvent promptly gets dimethyl RGD.
The preparation of dimethyl RGD-stearic amide: get etc. mole mole dimethyl RGD solution (dimethyl formamide is a solvent) and stearic acid N-butanimide solution (glycol dimethyl ether is a solvent) mixing, add triethylamine and make the reaction beginning in right amount, reaction is 48 hours under the room temperature.Removal of solvent under reduced pressure.
The preparation of RGD-stearic amide: get dimethyl RGD stearic amide and be dissolved in methanol, slowly splash into 1MNaOH solution, continue reaction 3 hours.Drip 1N HCl regulator solution to pH7.0.Through silica gel chromatography column chromatography (methanol is eluant), collect RGD-stearic amide part.Removing methanol gets final product.
Etoposide-mPEG-PDLLA-micellar the preparation of RGD-stearic amide
Take by weighing 50mg etoposide, 4.5mg RGD-stearic amide and 100mg mPEG-PDLLA respectively and place flask, add acetonitrile 50ml, be stirred to dissolving.Under constantly stirring, slowly drip 25ml water, continue to stir 15 minutes, further drip 75ml water.Slowly boil off acetonitrile (Rotary Evaporators) under 60 ℃, vacuum, after waiting not have obvious acetonitrile and steaming, elevated temperature and vacuum continue to steam to the about 80ml of sample volume, and samples with water is adjusted volume to 100ml.Product is with 0.22mm microporous filter membrane Entkeimung.
Etoposide-mPEG-PDLLA-RGD-stearic amide micelle cell toxicant (Cytotoxicity) experiment
Cytotoxicity test employing MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophonyl)-2H-tetrazolium, inner salt, Promega)) colorimetry.It is an amount of to get etoposide, RGD-stearic amide, mPEG-PDLLA, prepare the etoposide inj that etoposide concentration is 6mg/ml respectively (according to commercially available prescription preparation solvent: PEG 300 650mg, polyoxyethylene sorbitan monoleate 80mg, benzyl alcohol 30mg, citric acid 2mg, ethanol 30.5%v/v), etoposide-mPEG-PDLLA micelle dispersion liquid, etoposide-mPEG-PDLLA-RGD-stearic amide micelle dispersion liquid, pressure sterilizing respectively.Be diluted to the finite concentration test with water for injection respectively.
The test cell is respectively MDA-MB-435 breast cancer cell (HTB) and people's normal fiber archeocyte (NHEK).Respectively three kinds of prescriptions are diluted to 1000,500 with water for injection, 250,100,50,25,10,5,2.5,1, the serial solution trial of 0 μ mol/ml.Compare with blank solvent or micelle dispersion liquid.
The result shows and sees Table 2: etoposide inj (CE) and blank solvent (CS) toxicity thereof are bigger, and similar to the toxicity of normal cell and tumor cell; Etoposide-mPEG-PDLLA micelle dispersion liquid (BPE) and blank dispersion liquid (BP) toxicity thereof minimum (blank dispersion liquid does not all have overt toxicity to tumor cell and normal cell), and normal cell to the tolerance of etoposide-mPEG-PDLLA micelle dispersion liquid a little more than tumor cell; Etoposide-mPEG-PDLLA-RGD-stearic amide micelle dispersion liquid (RBPE) is 283.12 μ mole/ml to the IC50 of NHEK, IC50 to HTB is 62.25 μ mole/ml, and blank mPEG-PDLLA-RGD-stearic amide micelle dispersion liquid (RBP).
Various etoposide preparations of table 2 or blank preparation are to the IC50 (μ mole/ml) of NHEK and HTB
| Medicine | ?CE???????CS???????BPE???????BP????????RBPE??????RBP |
| ?NHEK | ?31.3?????38.82????333.33????＞1000????283.12????750.00 |
| ?HTB | ?80.77????81.77????71.43?????＞1000????62.25?????622.22 |
The micellar preparation of paclitaxel-mPEG-PDLLA
Take by weighing the 50mg paclitaxel respectively and the 100mg mPEG-PDLLA places flask, add acetonitrile 50ml, be stirred to dissolving.Under constantly stirring, slowly drip 25ml water, continue to stir 15 minutes, further drip 75ml water.Slowly boil off acetonitrile (Rotary Evaporators) under 60 ℃, vacuum, after waiting not have obvious acetonitrile and steaming, elevated temperature and vacuum continue to steam to the about 80ml of sample volume, and samples with water is adjusted volume to 100ml.Product is with 0.22mm microporous filter membrane Entkeimung.
Embodiment 7
Paclitaxel-mPEG-PDLLA-micellar the preparation of RGD-stearic amide
Take by weighing 50mg paclitaxel, 4.5mg RGD-stearic amide and 100mg mPEG-PDLLA respectively and place flask, add acetonitrile 50ml, be stirred to dissolving.Under constantly stirring, slowly drip 25ml water, continue to stir 15 minutes, further drip 75ml water.Slowly boil off acetonitrile (Rotary Evaporators) under 60 ℃, vacuum, after waiting not have obvious acetonitrile and steaming, elevated temperature and vacuum continue to steam to the about 80ml of sample volume, and samples with water is adjusted volume to 100ml.Product is with 0.22mm microporous filter membrane Entkeimung.
Description of drawings:
The GPC figure of Fig. 1 50/50 mPEG-PDLLA
The GPC figure of Fig. 2 20/80 mPEG-PDLLA
The GPC figure of Fig. 3 5/95 mPEG-PDLLA
The NMR figure of Fig. 4 50/50 mPEG-PDLLA
The NMR figure of Fig. 5 20/80 mPEG-PDLLA
The NMR figure of Fig. 6 5/95 mPEG-PDLLA
The DSC figure of Fig. 7 50/50 mPEG-PDLLA
The DSC figure of Fig. 8 20/80 mPEG-PDLLA
The DSC figure of Fig. 9 5/95 mPEG-PDLLA
Claims (10)
1. amphipathic nature polyalcohol, by the methyl Polyethylene Glycol, polyester is made, and it is characterized in that, and in the proportioning that copolymer is formed, the mass ratio of methyl Polyethylene Glycol and polyester is lower than 50/50.
2. the polymer of claim 1, polyester wherein is selected from, polylactic acid, polyglycolic acid (polyglycolide)), glycolide-lactide copolymer (poly (lactide-co-glycolide), PLGA).
3. the micellar preparation method of amphipathic nature polyalcohol is characterized in that, by the following steps preparation,
A. medicine and Amphipathilic block polymer are dissolved in the polar organic solvent,
B. drip and add water in the solution, or will make into microemulsion in the drips of solution entry,
C. boil off polar organic solvent.
4. the preparation method of claim 3, wherein said polar organic solvent is selected from, acetonitrile, ethanol, dimethyl sulfoxine (DMSO), dimethyl formamide, methanol, dichloromethane, chloroform.
5. an amphipathic nature polyalcohol micelle medicine carrying system is characterized in that, the drug delivery system that is aligned (hydrophilic group is outside, and lipophilic group is inside) by the micelle of the preparation method of claim 3 or 4 preparation is formed, and the medicine carrying is in micelle.
6. the drug-loading system of claim 5, its contained medicine is selected from, antitumor drug, antibiotic, cardiovascular drugs, antidiabetic medicine, NSAID (non-steroidal anti-inflammatory drug).
7. a tumour target polymer micelle administration system is characterized in that, this system is by antitumor drug, and claim 1 or 2 polymer are formed with the surfactant with cancer target characteristic.
8. the described polymer micelle administration of claim 7 system, wherein said surfactant with cancer target effect has the molecule of tumor affinity and the amphiphile, amphiphilic molecule that hydrophobic molecule is formed by hydrophilic.
9. the polymer micelle administration system of claim 8, the hydrophilic molecule that wherein has tumor affinity comprises following material, have the protein of tissue or cell-specific or polypeptide, somatomedin, vitamin and analog thereof, polysaccharide, glycopeptide or glycoprotein, steroidal and analog thereof, hormone, cofactor, genetic molecule, to brain special contain CNSRLHLRC, CENWWGDVC, the segmental polypeptide of WRCVLREGPAGGCAWFNRHRL and CLSSRLDAC, protein; Kidney-specific contained CLPVASC and the segmental polypeptide of CGAREMC, protein; To lung special contain CGFECVRQCPERC, CGFELETC, the segmental polypeptide of CTLRDRNC and CIGEVEVC, protein; To skin special contain the segmental polypeptide of CVALCREACGEGC, protein; To spleen special contain the segmental polypeptide of SWCEPGWCR, protein; To small intestinal special contain the segmental polypeptide of YSGKWGW, protein, to the uterus special contain the segmental polypeptide of GLSGGRS, protein; To the adrenal gland special contain the segmental polypeptide of LMLPRAD, protein; To retinal tissue special contain CRDVVSVIC and the segmental polypeptide of CSCFRDVCC, protein; Have the polypeptide, the protein that suppress integral protein express cell and extracellular matrix protein combination, this proteinoid or polypeptide contain CRGDC, CRGDCL, NGR (AHA), DGR (AHA), CRGDCA, RCDVVV, SLIDIP, TIRSVD, KRGD, RRGP and RGDL fragment; Antibody with tumour-specific; To the solid tumor tunica intima special contain CDCRGDCFC and the segmental polypeptide of CNGRCVSGCAGRC, protein; And other have the molecule of special affinity to tumor cell, during hydrophobic molecule is selected from, long-chain fatty acid, in, long-chain fatty alcohol, stearic acid, stearyl alcohol, spermaceti acid, spermol, lauric acid, lauryl alcohol.
10. the polymer micelle administration system of claim 7, wherein said antitumor drug is selected from paclitaxel, Docetaxel, camptothecine, etoposide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031053483A CN1296097C (en) | 2003-02-25 | 2003-02-25 | Polymer micelle medicine-carrying system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031053483A CN1296097C (en) | 2003-02-25 | 2003-02-25 | Polymer micelle medicine-carrying system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1524581A true CN1524581A (en) | 2004-09-01 |
| CN1296097C CN1296097C (en) | 2007-01-24 |
Family
ID=34282619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031053483A Expired - Fee Related CN1296097C (en) | 2003-02-25 | 2003-02-25 | Polymer micelle medicine-carrying system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1296097C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507706B (en) * | 2009-03-24 | 2011-07-20 | 涂家生 | Biodegradable in-situ solidification sustained-release injector |
| CN103461359A (en) * | 2013-09-26 | 2013-12-25 | 卞佳林 | Preparation method for spinosad/avilamycin composite polymeric micelle insecticide |
| CN103478145A (en) * | 2013-09-26 | 2014-01-01 | 卞佳林 | Spinosyn and avermectin composite polymeric micellar pesticide |
| CN103601878A (en) * | 2013-11-25 | 2014-02-26 | 沈阳药科大学 | High-stability polyethylene glycol-polyester polymer and application thereof |
| CN103768013A (en) * | 2014-01-17 | 2014-05-07 | 丽珠医药集团股份有限公司 | Paclitaxel polymer micelle by using refined amphiphilic block copolymer as carrier |
| CN104997758A (en) * | 2014-04-22 | 2015-10-28 | 复旦大学 | Paclitaxel entrapped polymeric micelle for treating tumors, and preparation method thereof |
| CN109821024A (en) * | 2019-04-08 | 2019-05-31 | 沈阳药科大学 | Co-loaded micelles of ROS generators and oxidatively responsive antitumor prodrugs and their applications |
| WO2023030474A1 (en) * | 2021-09-03 | 2023-03-09 | 先声药业有限公司 | Hydrophobic drug polymer micelle and preparation method therefor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321092A (en) * | 1998-06-30 | 2001-11-07 | 安姆根有限公司 | Thermosensitive biodegradable hydrogels for delayed drug delivery of bioactive agents |
-
2003
- 2003-02-25 CN CNB031053483A patent/CN1296097C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101507706B (en) * | 2009-03-24 | 2011-07-20 | 涂家生 | Biodegradable in-situ solidification sustained-release injector |
| CN103461359A (en) * | 2013-09-26 | 2013-12-25 | 卞佳林 | Preparation method for spinosad/avilamycin composite polymeric micelle insecticide |
| CN103478145A (en) * | 2013-09-26 | 2014-01-01 | 卞佳林 | Spinosyn and avermectin composite polymeric micellar pesticide |
| CN103601878A (en) * | 2013-11-25 | 2014-02-26 | 沈阳药科大学 | High-stability polyethylene glycol-polyester polymer and application thereof |
| CN103601878B (en) * | 2013-11-25 | 2015-05-13 | 沈阳药科大学 | High-stability polyethylene glycol-polyester polymer and application thereof |
| CN103768013A (en) * | 2014-01-17 | 2014-05-07 | 丽珠医药集团股份有限公司 | Paclitaxel polymer micelle by using refined amphiphilic block copolymer as carrier |
| CN104997758A (en) * | 2014-04-22 | 2015-10-28 | 复旦大学 | Paclitaxel entrapped polymeric micelle for treating tumors, and preparation method thereof |
| CN109821024A (en) * | 2019-04-08 | 2019-05-31 | 沈阳药科大学 | Co-loaded micelles of ROS generators and oxidatively responsive antitumor prodrugs and their applications |
| WO2023030474A1 (en) * | 2021-09-03 | 2023-03-09 | 先声药业有限公司 | Hydrophobic drug polymer micelle and preparation method therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1296097C (en) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5842270B2 (en) | Micelle composition and method for its preparation | |
| JP4537641B2 (en) | Stable polymer micelle form drug composition | |
| CN103772686B (en) | Amphiphilic block copolymer and preparation method thereof, micelle drug delivery system formed by copolymer and anti-tumor drug | |
| Lee et al. | The use of cholesterol-containing biodegradable block copolymers to exploit hydrophobic interactions for the delivery of anticancer drugs | |
| RU2523714C2 (en) | Polymer systems of delivering active substances | |
| Xie et al. | Release modulation and cytotoxicity of hydroxycamptothecin-loaded electrospun fibers with 2-hydroxypropyl-β-cyclodextrin inoculations | |
| CN101972480B (en) | Docetaxel polymeric micelle medicine composition taking amino acid as stabilizing agent | |
| AU2001262756A1 (en) | Stable polymeric micelle-type drug composition and method for the preparation thereof | |
| Chu et al. | PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery | |
| CZ20024268A3 (en) | Preparation producing micelles | |
| DK1532985T3 (en) | PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE | |
| AU2016374669A1 (en) | Biodegradable amphiphilic polymer, polymer vesicle prepared therefrom and use in preparing target therapeutic medicine for lung cancer | |
| CN1296097C (en) | Polymer micelle medicine-carrying system | |
| CN106983719A (en) | A kind of docetaxel polymer nano micelle injection, its preparation method and its application in tumor is prepared | |
| Gao et al. | Hydrotropic polymer-based paclitaxel-loaded self-assembled nanoparticles: preparation and biological evaluation | |
| KR100488002B1 (en) | Amphiphilic block copolymer consisting of hydrophilic polyalkylene glycol block and hydrophobic block, copolymer of aromatic side chain - containing α-hydroxyl acid derivatives and lactides | |
| EP4475895A1 (en) | Locally administered compositions and methods of use thereof | |
| CN104211933A (en) | Preparation method of polymeric microsphere capable of encapsulating difficultly soluble antitumor drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WU JIANMEI; TU JIASHENG Free format text: FORMER OWNER: WU JIANMEI Effective date: 20070112 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070112 Address after: 210037, Jiangsu, Nanjing, Heilongjiang Road, Lin oasis, room 1-1105 Co-patentee after: Tu Jiasheng Patentee after: Wu Jianmei Address before: 210008 Jiangsu Province, Nanjing Fujian road Huafu building room 1908 Patentee before: Wu Jianmei |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20040901 Assignee: Sichuan Taiji Pharmaceutical Co., Ltd. of Taiji Group Assignor: Wu Jianmei Contract record no.: 2014500000055 Denomination of invention: Polymer micelle medicine-carrying system Granted publication date: 20070124 License type: Common License Record date: 20140804 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070124 Termination date: 20180225 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |